Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib plus platinum-based chemotherapy for platinum-sensitive relapsed ovarian cancer
ACTRN12610000160033Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of cediranib in ovarian cancer, fallopian tube cancer (PFTC) and serous peritoneal carcinoma (PPSC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jan 2011; status: active, not recruiting.
02
Drugs
cediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on ACTRN12610000160033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000160033.